SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS reported completion of a Phase 1 study of SCY-770, an oral direct AMPK activator, in healthy adults. The company said SCY-770 was well tolerated across dose cohorts and that a Phase 2 proof-of-concept study in ADPKD patients remains on-track to initiate in the fourth quarter of 2026.